Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 42 Women only

Using oral dydrogesterone to support pregnancy in natural cycle frozen embryo transfers

Official title: A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer

Run by The University of Hong Kong · NCT03859921 · Data updated 2026-11-12

This study is testing if taking a pill called dydrogesterone can help women under 43 who are having frozen embryo transfers have a better chance of a successful pregnancy.

More Subfertility trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 42 Years
SexWomen only
Enrollment716 (estimated)
SponsorThe University of Hong Kong
Academic / other
Locations1 site (Hong Kong, Hong Kong)
StatusRecruiting
StartedJuly 1, 2021
Main results expectedDecember 30, 2025
Study endsNovember 30, 2026
Registry record updatedJune 12, 2025
Trial IDNCT03859921 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women under 43 years old who are undergoing frozen embryo transfer with early cleavage embryos or blastocysts.

Probably not a fit

Patients who require hormonal replacement cycles, use donor oocytes or embryos, or have not corrected hydrosalpinx prior to FET may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized double-blinded controlled trial aims to evaluate the effectiveness of oral dydrogesterone in increasing live birth rates during natural frozen embryo transfer (FET) cycles. Women undergoing FET at the University of Hong Kong-Queen Mary Hospital will be randomly assigned to receive either oral dydrogesterone or a placebo for two weeks following ovulation. The study will monitor the outcomes of these treatments to determine if dydrogesterone provides a significant benefit in supporting pregnancy. The trial focuses on women under 43 years of age who are undergoing FET with thawed embryos.

Why it matters

Potential benefit: If successful, this study could improve live birth rates for women undergoing natural cycle frozen embryo transfers.

How similar studies have gone: Other studies have shown promising results with similar approaches, suggesting that dydrogesterone may enhance pregnancy outcomes in assisted reproductive technologies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age of women \<43 years at the time of stimulated IVF
* Replacing early cleavage embryos or blastocysts after thawing

Exclusion Criteria:

* Requiring hormonal replacement cycles
* Use of donor oocytes or embryos
* Undergoing preimplantation genetic testing
* Presence of hydrosalpinx not corrected surgically prior to FET
* Refusal to join the study

Where it's running

  • Department of Obstetrics and Gynaecology
    Hong Kong, Hong Kong, China
    Recruiting

Study contacts

  • Principal investigator: Ernest HY Ng, MD — The University of Hong Kong
  • Study coordinator: Ernest HY Ng, MD
  • Email: nghye@hku.hk
  • Phone: 852-28553400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.